Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program.
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2015
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 06 Jul 2010 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
- 01 May 2010 Results published in the American Journal of Medicine.
- 01 May 2010 Primary endpoint 'Bodyweight reduction' has been met according to results published in the American Journal of Medicine.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History